$AWH
Aspira Women's Health Inc.

2024 Q1 Form 10-K Financial Statement

#000092661724000015 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $2.153M $2.130M $9.154M
YoY Change -7.04% -1.07% 11.85%
Cost Of Revenue $939.0K $911.0K $3.892M
YoY Change -16.53% -0.65% 0.7%
Gross Profit $1.214M $1.219M $5.262M
YoY Change 1.93% -1.38% 21.83%
Gross Profit Margin 56.39% 57.23% 57.48%
Selling, General & Admin $5.018M $4.277M $20.08M
YoY Change -12.41% -26.25% -35.5%
% of Gross Profit 413.34% 350.86% 381.58%
Research & Development $906.0K $1.077M $4.035M
YoY Change -26.4% 3.76% -32.22%
% of Gross Profit 74.63% 88.35% 76.68%
Depreciation & Amortization $29.00K $39.00K $199.0K
YoY Change -58.57% -43.48% -24.62%
% of Gross Profit 2.39% 3.2% 3.78%
Operating Expenses $5.924M $5.354M $24.11M
YoY Change -14.89% -21.69% -34.97%
Operating Profit -$4.710M -$4.135M -$18.85M
YoY Change -18.36% -26.17% -42.46%
Interest Expense -$5.000K $2.000K $48.00K
YoY Change -119.23% -92.59% 182.35%
% of Operating Profit
Other Income/Expense, Net $81.00K $44.00K $1.114M
YoY Change -127.0% -90.7% -80.03%
Pretax Income -$4.629M -$3.089M -$16.69M
YoY Change -23.7% -39.44% -38.57%
Income Tax
% Of Pretax Income
Net Earnings -$4.629M -$3.089M -$16.69M
YoY Change -23.7% -39.44% -38.57%
Net Earnings / Revenue -215.0% -145.02% -182.32%
Basic Earnings Per Share -$0.39 -$1.81
Diluted Earnings Per Share -$0.39 -$0.30 -$1.81
COMMON SHARES
Basic Shares Outstanding 12.34M 10.34M 9.233M
Diluted Shares Outstanding 11.85M 9.233M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.413M $2.597M $2.597M
YoY Change -54.7% -80.48% -80.48%
Cash & Equivalents $3.413M $2.597M $2.597M
Short-Term Investments
Other Short-Term Assets $162.0K $997.0K $997.0K
YoY Change -85.75% -30.86% -30.86%
Inventory $236.0K $227.0K $227.0K
Prepaid Expenses
Receivables $1.531M $1.459M $1.459M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.122M $5.280M $5.280M
YoY Change -41.85% -67.63% -67.63%
LONG-TERM ASSETS
Property, Plant & Equipment $131.0K $693.0K $693.0K
YoY Change -57.05% 6.62% 6.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $31.00K $289.0K $289.0K
YoY Change -78.62% -30.19% -30.19%
Total Long-Term Assets $1.042M $982.0K $982.0K
YoY Change 7.64% -7.71% -7.71%
TOTAL ASSETS
Total Short-Term Assets $6.122M $5.280M $5.280M
Total Long-Term Assets $1.042M $982.0K $982.0K
Total Assets $7.164M $6.262M $6.262M
YoY Change -37.68% -63.96% -63.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.643M $1.261M $1.261M
YoY Change 89.5% 43.13% 43.13%
Accrued Expenses $2.797M $3.022M $3.022M
YoY Change -29.79% -18.92% -18.92%
Deferred Revenue
YoY Change
Short-Term Debt $416.0K $670.0K $670.0K
YoY Change -22.24% -12.3% -12.3%
Long-Term Debt Due $249.0K $166.0K $166.0K
YoY Change -43.67% -58.81% -58.81%
Total Short-Term Liabilities $5.293M $5.119M $5.119M
YoY Change -10.46% -11.36% -11.36%
LONG-TERM LIABILITIES
Long-Term Debt $1.347M $1.430M $1.430M
YoY Change -38.88% -38.23% -38.23%
Other Long-Term Liabilities $1.887M $2.078M $2.078M
YoY Change -26.12% -18.57% -18.57%
Total Long-Term Liabilities $1.347M $3.508M $3.508M
YoY Change -38.88% -27.92% -27.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.293M $5.119M $5.119M
Total Long-Term Liabilities $1.347M $3.508M $3.508M
Total Liabilities $8.527M $8.627M $8.627M
YoY Change -20.08% -18.93% -18.93%
SHAREHOLDERS EQUITY
Retained Earnings -$522.9M -$518.3M
YoY Change 3.56% 3.89%
Common Stock $521.6M $11.00K
YoY Change 6519512.5% -91.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.363M -$2.365M -$2.365M
YoY Change
Total Liabilities & Shareholders Equity $7.164M $6.262M $6.262M
YoY Change -37.68% -63.96% -63.96%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$4.629M -$3.089M -$16.69M
YoY Change -23.7% -39.44% -38.57%
Depreciation, Depletion And Amortization $29.00K $39.00K $199.0K
YoY Change -58.57% -43.48% -24.62%
Cash From Operating Activities -$4.431M -$3.454M -$15.89M
YoY Change -22.34% -51.19% -50.64%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $14.00K $24.00K
YoY Change 150.0% -81.08% -89.66%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K -$14.00K -$24.00K
YoY Change 150.0% -81.08% -89.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.498M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.269M 956.0K 5.216M
YoY Change -9680.0% -1117.02% -38.95%
NET CHANGE
Cash From Operating Activities -4.431M -3.454M -15.89M
Cash From Investing Activities -20.00K -14.00K -24.00K
Cash From Financing Activities 5.269M 956.0K 5.216M
Net Change In Cash 818.0K -2.512M -10.70M
YoY Change -114.18% -65.32% -55.17%
FREE CASH FLOW
Cash From Operating Activities -$4.431M -$3.454M -$15.89M
Capital Expenditures $20.00K $14.00K $24.00K
Free Cash Flow -$4.451M -$3.468M -$15.92M
YoY Change -22.1% -51.5% -50.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 awh Right Of Use Asset Net
RightOfUseAssetNet
CY2022Q4 awh Right Of Use Liability Net
RightOfUseLiabilityNet
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000926617
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2023 us-gaap Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration
GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2022 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-34810
CY2023 dei Entity Registrant Name
EntityRegistrantName
Aspira Women’s Health Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
CY2023 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
CY2023 dei City Area Code
CityAreaCode
512
CY2023 dei Local Phone Number
LocalPhoneNumber
519-0400
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
AWH
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
17677058
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12344104
CY2023 dei Auditor Firm
AuditorFirmId
243
CY2023 dei Auditor Name
AuditorName
BDO USA, P.C
CY2023 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2597000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13306000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
15000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
9000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1459000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1245000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
997000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1442000
CY2023Q4 us-gaap Inventory Net
InventoryNet
227000
CY2022Q4 us-gaap Inventory Net
InventoryNet
316000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5280000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
16309000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
368000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
528000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
282000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
258000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
251000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
31000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
163000
CY2023Q4 us-gaap Assets
Assets
6262000
CY2022Q4 us-gaap Assets
Assets
17373000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1261000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
881000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2863000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3402000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
166000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
403000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
670000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
764000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
159000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
77000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5119000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5527000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1430000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2315000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
427000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1651000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2280000
CY2023Q4 us-gaap Liabilities
Liabilities
8627000
CY2022Q4 us-gaap Liabilities
Liabilities
10394000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10645049
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10645049
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8306326
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8306326
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
515927000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
508584000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-518303000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-501613000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2365000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6979000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6262000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17373000
CY2023 us-gaap Revenues
Revenues
9154000
CY2022 us-gaap Revenues
Revenues
8184000
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3892000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3861000
CY2023 us-gaap Gross Profit
GrossProfit
5262000
CY2022 us-gaap Gross Profit
GrossProfit
4323000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4035000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5917000
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7812000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14915000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12267000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14629000
CY2023 us-gaap Operating Expenses
OperatingExpenses
24114000
CY2022 us-gaap Operating Expenses
OperatingExpenses
35461000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-18852000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-31138000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-629000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1704000
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
48000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
17000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
485000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-468000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2162000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1253000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-16690000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29885000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.85
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.85
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.85
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9233306
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9233306
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9233306
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7769109
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7769109
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7769109
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29885000
CY2022 awh Common Stock Issued In Conjunction With Exercise Of Stock Options
CommonStockIssuedInConjunctionWithExerciseOfStockOptions
13000
CY2022 awh Common Stock And Warrants Issued Value
CommonStockAndWarrantsIssuedValue
4266000
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
362000
CY2022 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
2051000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6979000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-16690000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
68000
CY2023 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1177000
CY2023 awh Commonstock Value Issued For Entering Into Equity Line Of Credit
CommonstockValueIssuedForEnteringIntoEquityLineOfCredit
258000
CY2023 awh Common Stock Issued Under Registered Direct Offering Net Of Issuance Costs
CommonStockIssuedUnderRegisteredDirectOfferingNetOfIssuanceCosts
4119000
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
815000
CY2023 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
909000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2365000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-16690000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29885000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
-9000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
199000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
264000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1724000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2414000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-629000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1704000
CY2022 awh Other Expenses Representing Transaction Costs Allocated To Issuance Of Warrants
OtherExpensesRepresentingTransactionCostsAllocatedToIssuanceOfWarrants
574000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-28000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-64000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
258000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
214000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
218000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-577000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-89000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
142000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
380000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-620000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-539000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1838000
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-68000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-14000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15894000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31068000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
232000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232000
CY2023 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
148000
CY2022 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
261000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
202000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
134000
CY2023 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1177000
CY2023 awh Proceeds From Registered Direct Offering
ProceedsFromRegisteredDirectOffering
4716000
CY2023 awh Payment Of Issuance Costs For Registered Direct Offering
PaymentOfIssuanceCostsForRegisteredDirectOffering
597000
CY2022 awh Proceeds From Public Offering
ProceedsFromPublicOffering
9000000
CY2022 awh Payment Of Issuance Costs For Public Offering
PaymentOfIssuanceCostsForPublicOffering
1325000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5216000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7427000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10702000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23873000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13557000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2855000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13557000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2597000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13306000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
258000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
251000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2855000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13557000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
45000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
77000
CY2023 awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
318000
CY2022 awh Warrants Issued Fair Value
WarrantsIssuedFairValue
3984000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-518300000
CY2023Q4 awh Working Capital
WorkingCapital
200000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-16700000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15900000
CY2023Q4 awh Market Capitalisation
MarketCapitalisation
35000000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, warrants, income taxes and contingent liabilities. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Concentration of Credit Risk</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2022Q4 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2023Q4 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2023 us-gaap Finite Lived Intangible Assets Cost Incurred To Renew Or Extend
FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend
341000
CY2022 us-gaap Finite Lived Intangible Assets Cost Incurred To Renew Or Extend
FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend
410000
CY2023 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
347000
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
346820
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1981000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3179000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1816000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2811000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
368000
CY2023 us-gaap Depreciation
Depreciation
199000
CY2022 us-gaap Depreciation
Depreciation
265000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
52000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1189000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1803000
CY2023Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
217000
CY2022Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
404000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
951000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
556000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
506000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
639000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2863000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3402000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1596000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
2718000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
166000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
403000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1430000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2315000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
427000
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
1604000
CY2023Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
170000
CY2023Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
335000
CY2023Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
342000
CY2023Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
215000
CY2023Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
129000
CY2023Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
413000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
194000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
167000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
171000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
84000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
52000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
668000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
82000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
586000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
159000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
459000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
362000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0730
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0930
CY2023 us-gaap Royalty Expense
RoyaltyExpense
324000
CY2022 us-gaap Royalty Expense
RoyaltyExpense
318000
CY2023 us-gaap Severance Costs1
SeveranceCosts1
1284000
CY2023 awh Insurance Reimbursement Including Not Paid
InsuranceReimbursementIncludingNotPaid
523000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.20
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
799985
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
799985
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
366664
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.20
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-16690000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29885000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9233306
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7769109
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.85
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
248613
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
201275
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
174175
CY2022 awh Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Restricted Stock Units Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantRestrictedStockUnitsCancelledInPeriod
-346
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
29223
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
8404
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
238432
CY2023 awh Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Additional Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAdditionalShares
333333
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
292809
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
397503
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
259161
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
42049
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
165861
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
683861
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
44.40
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3797181000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M8D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
174175
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.17
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1533
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.13
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
201275
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
68.12
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
655228
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.25
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y21D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
397503
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.57
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
292809
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.90
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
759922
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.48
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
113929000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M13D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
452606
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
22.57
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
33073000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
201328
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
10.31
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
41992000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y5M12D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6073000000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5982000000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.383
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.927
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0445
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0245
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05
CY2023 awh Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
4.160
CY2022 awh Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
7.350
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1724000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2414000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y6M
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16700000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29900000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
52540000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44509000
CY2023Q4 awh Deferred Tax Assets Intangible Assets Amortization
DeferredTaxAssetsIntangibleAssetsAmortization
3432000
CY2022Q4 awh Deferred Tax Assets Intangible Assets Amortization
DeferredTaxAssetsIntangibleAssetsAmortization
3686000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
487000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
678000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
697000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
804000
CY2023Q4 awh Right Of Use Liability Net
RightOfUseLiabilityNet
137000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57293000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49677000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57170000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49677000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
123000
CY2023Q4 awh Right Of Use Asset Net
RightOfUseAssetNet
123000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
123000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.17
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.26
CY2023 awh Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants
0.01
CY2022 awh Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrants
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants
0.01
CY2023 awh Effective Income Tax Rate Reconciliation Net Operating Loss Carry Forwards
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryForwards
-0.01
CY2023 awh Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.01
CY2022 awh Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
-0.01
CY2023 awh Effectiveincometaxratereconciliationdeferred Adjustmentsreturn To Provision
EffectiveincometaxratereconciliationdeferredAdjustmentsreturnToProvision
-0.03
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57200000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49700000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10581000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
435000
CY2022 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
785000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10231000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
493000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10724000
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
366664
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.20

Files In Submission

Name View Source Status
0000926617-24-000015-index-headers.html Edgar Link pending
0000926617-24-000015-index.html Edgar Link pending
0000926617-24-000015.txt Edgar Link pending
0000926617-24-000015-xbrl.zip Edgar Link pending
awh-20231231.xsd Edgar Link pending
awh-20231231x10k.htm Edgar Link pending
awh-20231231xex10_18.htm Edgar Link pending
awh-20231231xex10_28.htm Edgar Link pending
awh-20231231xex23_1.htm Edgar Link pending
awh-20231231xex31_1.htm Edgar Link pending
awh-20231231xex31_2.htm Edgar Link pending
awh-20231231xex32_1.htm Edgar Link pending
awh-20231231xex4_7.htm Edgar Link pending
awh-20231231xex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
awh-20231231_def.xml Edgar Link unprocessable
awh-20231231_lab.xml Edgar Link unprocessable
awh-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
awh-20231231x10k_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
awh-20231231_cal.xml Edgar Link unprocessable